LivagenLongevity

Livagen is a synthetic tetrapeptide, lysine-glutamate-aspartate-alanine (Lys-Glu-Asp-Ala / KEDA), developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the same "ultrashort peptide bioregulator" family as epitalon and pinealon, and is marketed around the liver, immune cells and the gastrointestinal tract.

Two facts should frame everything that follows. First, every published Livagen finding comes from cell culture or rats — there is not one human clinical trial. Second, the literature is small and concentrated: roughly a dozen papers, nearly all from the Khavinson group or a collaborating Tbilisi group, published largely in Russian and Georgian journals with little independent replication. It is not FDA-evaluated and is sold only as a research chemical.

A common misreading. Livagen is often described as having been "studied in subjects aged 75 to 88." Those people were cell donors, not participants. Their lymphocytes were drawn and the peptide was added to the cells in a dish. No one in that research was given Livagen.

Livagen has no identified receptor or validated molecular target. Its proposed mechanism comes from the broader Khavinson "peptide bioregulation" theory: peptides this small are hypothesized to reach the cell nucleus and interact with DNA and histones, changing which genes are accessible.

The specific claim for Livagen is chromatin decondensation. In cultured lymphocytes from elderly donors, the group reported activation of ribosomal genes, loosening of pericentromeric structural heterochromatin, and de-repression of euchromatic regions that had condensed with age. The interpretation offered is that Livagen "un-silences" genes switched off by aging.

A separate in-vitro finding is that Livagen inhibits enkephalin-degrading enzymes in human serum, which is where claims about an endogenous-opioid effect originate. Worth noting: the reported IC50 was about 20 µM — a concentration far above anything a typical peptide dose would plausibly produce in circulation, which makes the physiological relevance doubtful.

Whether any of this reflects a real action in a living human is unresolved, because none of it has been tested in one.

There is no human clinical evidence for Livagen — no randomized trials, no controlled studies, no pharmacokinetics, no human efficacy or safety data. What exists is preclinical:

The rat feeding study is the strongest design in the set: over two weeks of oral dosing, digestive enzyme activity fell in young rats but rose in old ones, in many cases back toward young-animal levels. That is a genuine in-vivo result — in rats, in a specialist gerontology journal, and not independently replicated.

Notably, the "liver" association that the product's name evokes rests on a single 2002 rat organotypic-culture study. There is no human liver data of any kind.

Livagen's human safety is entirely uncharacterized. There are no controlled human trials, no adverse-event reporting, no pharmacokinetics, and no long-term follow-up. Preclinical work has not flagged obvious toxicity, but absence of evidence in rats and cell cultures is not evidence of safety in people.

Two cautions deserve weight. A compound whose proposed mechanism is decondensing chromatin and de-repressing silenced genes is not obviously benign without long-term human data — the same gene-silencing it aims to reverse also suppresses genes for good reasons. And gray-market research material carries unverified identity, purity and sterility risk; Livagen is obscure enough that mislabeling is a realistic concern.

It is not a medicine, not FDA-approved, and not named on the WADA list (though novel peptides can fall under catch-all provisions). Given the YMYL stakes, both safety and human-data confidence are scored at the floor. Research use only — nothing here is medical or dosing advice.